Amy Winter
Family · Jackson, MNNPI 1790750875
Payments from drug & device makers
Across 39 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$65
- Organogenesis Inc.$52
- Novo Nordisk$47
- Johnson & Johnson$47
- Kowa Pharmaceuticals America, Inc.$37
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$35
- plus $322 from 17 others
What the payments were for
- Food & beverage$605100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| Organogenesis Inc. | 3 | $52 |
| Novo Nordisk | 3 | $47 |
| Johnson & Johnson | 3 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Amgen | 2 | $29 |
| Grifols USA, LLC | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 2 | $27 |
| Bayer | 2 | $27 |
| Dexcom, Inc. | 1 | $27 |
| Novartis | 1 | $20 |
| Abbott | 1 | $18 |
| Corium, LLC | 1 | $17 |
| AbbVie | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Sanofi | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
| Pfizer | 1 | $12 |
How this compares
$605 in reported general payments places this provider in the 85th percentile of 1,121 family providers in Minnesota.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 59 | $49,180 |
| JanuviaSitagliptin Phosphate | 17 | $20,179 |
| XareltoRivaroxaban | 18 | $16,859 |
| OzempicSemaglutide | 15 | $13,064 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,263 |
| MyrbetriqMirabegron | 13 | $5,914 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $3,653 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,645 |
| Levothyroxine Sodium | 138 | $1,825 |
| Varenicline Tartrate | 13 | $1,557 |
| Gabapentin | 104 | $1,535 |
| Ventolin HfaAlbuterol Sulfate | 13 | $1,463 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 65 | $1,365 |
| Travoprost | 11 | $1,330 |
| SynthroidLevothyroxine Sodium | 19 | $1,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $49,18059 claims |
| Johnson & JohnsonXarelto | $47 | $16,85918 claims |
| Novo NordiskOzempic | $47 | $13,06415 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $5,91413 claims |
| AbbVieSynthroid | $16 | $1,18819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,121 family providers in Minnesota.
Other family in Jackson
- Erin HewittMinnetonka$172K
- Julia GourdeMinneapolis$65K
- Robin DontaMinneapolis$60K
- Kristin WeberMinneapolis$35K
- Crista WenischBurnsville$30K
- Kathleen FredellMinneapolis$28K
- Christina RichardsonNorthfield$27K
- Diana CzelMinneapolis$24K
- Alesya ShumkovMinnetonka$22K
- Michelle HigginsStewartville$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.